Department of Medical Sociology, Institute of Epidemiology and Preventive Medicine, University of Regensburg, Dr.-Gessler-Str. 17, 93051, Regensburg, Germany.
VU University Medical Center, Department of Epidemiology and Biostatistics, EMGO+ Institute for Health and Care Research, Amsterdam, the Netherlands.
Br J Dermatol. 2017 Apr;176(4):878-889. doi: 10.1111/bjd.14966. Epub 2017 Feb 16.
Quality of life (QoL) is one of the core outcome domains identified by the Harmonising Outcome Measures for Eczema (HOME) initiative to be assessed in every eczema trial. There is uncertainty about the most appropriate QoL instrument to measure this domain in infants, children and adolescents.
To systematically evaluate the measurement properties of existing measurement instruments developed and/or validated for the measurement of QoL in infants, children and adolescents with eczema.
A systematic literature search in PubMed and Embase, complemented by a thorough hand search of reference lists, retrieved studies on measurement properties of eczema QoL instruments for infants, children and adolescents. For all eligible studies, we judged the adequacy of the measurement properties and the methodological study quality with the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist. Results from different studies were summarized in a best-evidence synthesis and formed the basis to assign four degrees of recommendation.
Seventeen articles, three of which were found by hand search, were included. These 17 articles reported on 24 instruments. No instrument can be recommended for use in all eczema trials because none fulfilled all required adequacy criteria. With adequate internal consistency, reliability and hypothesis testing, the U.S. version of the Childhood Atopic Dermatitis Impact Scale (CADIS), a proxy-reported instrument, has the potential to be recommended depending on the results of further validation studies. All other instruments, including all self-reported ones, lacked significant validation data.
Currently, no QoL instrument for infants, children and adolescents with eczema can be highly recommended. Future validation research should primarily focus on the CADIS, but also attempt to broaden the evidence base for the validity of self-reported instruments.
生活质量(QoL)是 Harmonising Outcome Measures for Eczema(HOME)倡议确定的核心结局领域之一,需要在每一项湿疹试验中进行评估。目前尚不确定在婴儿、儿童和青少年中评估这一领域最适合的 QoL 测量工具。
系统评价已开发和/或验证用于评估湿疹婴儿、儿童和青少年生活质量的现有测量工具的测量特性。
在 PubMed 和 Embase 中进行系统文献检索,并对手头的参考文献进行全面搜索,以检索关于湿疹 QoL 测量工具的测量特性的研究。对于所有合格的研究,我们使用共识基础的健康测量工具选择标准(COSMIN)检查表来判断测量特性和方法学研究质量的充分性。来自不同研究的结果在最佳证据综合中进行了总结,并为分配四级推荐提供了依据。
共纳入 17 篇文章,其中 3 篇通过手工搜索发现。这 17 篇文章报告了 24 种工具。由于没有一种工具满足所有必需的充分性标准,因此没有一种工具可以推荐用于所有湿疹试验。美国版儿童特应性皮炎影响量表(CADIS)是一种代理报告工具,具有足够的内部一致性、可靠性和假设检验,有可能根据进一步验证研究的结果被推荐使用。所有其他工具,包括所有自我报告工具,都缺乏重要的验证数据。
目前,尚无一种针对湿疹婴儿、儿童和青少年的 QoL 测量工具可以得到高度推荐。未来的验证研究应主要集中在 CADIS 上,但也应尝试拓宽自我报告工具有效性的证据基础。